BioPharma Reporter
DECEMBER 22, 2020
Ajinomoto Bio-Pharma Services and Revance Therapeutics have announced a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for Injection.
pharmaphorum
MARCH 18, 2022
Allergan fell foul of the regulations for a number of LinkedIn and Instagram posts promoting Botox (botulinum toxin type A) to the public by the chief executive of aesthetics clinic – described in his profile as an ‘Allergan mentee’, which were also liked or commented on by employees of the company.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 2, 2022
The total value of the deal could rise to $1 billion, dependent on whether Syndesi’s SV2A drugs – headed by early-stage clinical candidate SDI-118 – progress in development and reach the market.
pharmaphorum
FEBRUARY 12, 2021
In 2020, Allergan opened a global Botox manufacturing facility in Westport, a tourist town on the west coast of Ireland and biotech company Regeneron established a biologic plant in Limerick. While we have a very proven value proposition with the US, it has been difficult to get to understand the Asian market.
The Pharma Data
FEBRUARY 4, 2021
– Full-Year Global Net Revenues from the Aesthetics Portfolio Were $2.590 Billion; Global Botox Cosmetic Net Revenues Were $1.112 Billion. – Full-Year Global Net Revenues from the Neuroscience Portfolio Were $3.496 Billion; Global Botox Therapeutic Net Revenues Were $1.387 Billion; Global Vraylar Net Revenues Were $951 Million.
XTalks
AUGUST 2, 2023
Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.
Expert insights. Personalized for you.
52 
Let's personalize your content